Cyclacel Pharmaceuticals, Inc. 6% Convertible Preferred Stock, also called Cyclacel Pharmaceuticals (Preferred), is a clinical stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ. The listed name for CYCCP is Cyclacel Pharmaceuticals, Inc. 6% Convertible Preferred Stock.